140382-35-0

Usage

Uses

Used in Pharmaceutical Industry:
2-Benzofurancarboxaldehyde, 5-fluorois used as a key intermediate in the synthesis of chiral benzofuryl β-nitro alcohols, which are important for the development of pharmaceutical compounds. The catalytic asymmetric Henry reaction allows for the selective formation of these chiral molecules, which are crucial in the design of drugs with improved efficacy and reduced side effects.
Used in Chemical Synthesis:
In the field of chemical synthesis, 2-Benzofurancarboxaldehyde, 5-fluoroserves as a versatile building block for the creation of a wide range of organic compounds. Its unique structure and reactivity make it a valuable component in the synthesis of various molecules with potential applications in different industries, such as agrochemicals, materials science, and specialty chemicals.

Upstream product

• 276235-91-7 (5-fluorobenzofuran-2-yl)methanol 
• 93849-31-1 ethyl 5-fluoro-1H-benzofuran-2-carboxylate 
• 347-54-6 5-fluoro-2-hydroxybenzaldehyde 
• 371-41-5 4-Fluorophenol 
• 179728-59-7 2-(2,2-diethoxyethoxy)-5-fluorobenzaldehyde 

Downstream Products

• 276235-91-7 (5-fluorobenzofuran-2-yl)methanol 

Relevant academic research and scientific papers

PYRROLIDINE COMPOUNDS FOR THE TREATMENT OF MALARIA

Pyrrolidine derivatives of formula I are used as anti-malaria agents, wherein the variables are as defined herein. Method of employing such agents in the treatment and prevention of malaria are also provided herein.

COMPOUNS, COMPOSITIONS AND METHODS OF USE

Herein, compounds, compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, and viral infections are described.

Efficient synthesis of chiral benzofuryl β-amino alcohols via a catalytic asymmetric Henry reaction

Chiral β-amino alcohol ligands were found effective for the copper(ii)-catalyzed asymmetric Henry reaction of benzofuran-2-carbaldehydes with nitromethane, which led to the formation of (S)-enriched benzofuryl β-nitro alcohols with satisfactory enantioselectivities (up to 98% ee). Using this catalytic protocol, bioactive (S)-benzofuryl β-amino alcohols could be conveniently prepared in short steps.

SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS

The present invention relates to novel spiro-oxadiazoline compounds that are suitable as agonists or partial agonists of a7-nAChR, and pharmaceutical compositions of the same, methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering a spiro-oxadiazoline cx7-nAChR agonist or partial agonist, to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS

The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer.

3-Benzo[b]furyl- and 3-benzo[b]thienylaminobutyric acids as GABA(B) ligands. Synthesis and structure-activity relationship studies

Baclofen (β-p-chlorophenyl GABA) is one of the selective agonists for the bicuculline-insensitive GABA(B) receptors. In the search for new compounds that bind to GABA(B) receptors it is very important to clarify the structural requirements. We report the syntheses of and binding studies on various 3- heteroaromatic (benzo[b]furan and benzo[b]thiophen)aminobutyric acids. The 4- amino-3-(7-methyl-benzo[b]furan-2-yl)butanoic acid 8g is a potent and specific ligand for GABA(B) receptors, with an IC50 value of 5.4 μM in the displacement of [3H]GABA.